Jaguar Health is a technology company.
Jaguar Health has raised $7.0M across 1 funding round.
Jaguar Health has raised $7.0M in total across 1 funding round.
Jaguar Health is a commercial-stage pharmaceutical company specializing in plant-based, sustainably derived prescription medicines primarily targeting gastrointestinal (GI) disorders in humans and animals. Its flagship product, Mytesi (crofelemer), is the only FDA-approved oral botanical drug for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar Health is expanding crofelemer’s use into rare GI diseases such as microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF), leveraging orphan drug economics and regulatory support to address unmet medical needs and capture premium market segments[1][2][3].
Founded with a mission to develop novel, plant-derived pharmaceuticals from rainforest sources, Jaguar Health’s portfolio includes multiple crofelemer formulations in various stages of development, aiming to treat chronic diarrhea, GI urgency, and incontinence. The company serves patients with debilitating GI conditions, offering a non-opioid alternative that normalizes gut function without typical side effects. Its growth momentum is driven by ongoing clinical trials, label expansion initiatives, and early access programs in Europe, positioning Jaguar Health at the intersection of botanical innovation and rare disease therapeutics[1][2][3].
---
Jaguar Health was established as a pioneer in botanical pharmaceutical innovation, focusing on Croton lechleri tree sap (crofelemer) from the Amazon Rainforest. The company’s founders and leadership leveraged this unique natural resource to create a first-in-class anti-secretory drug with FDA approval. The idea emerged from the need for safer, effective treatments for chronic diarrhea without opioid-related side effects. Early traction came with FDA approval of Mytesi and subsequent expansion into orphan GI diseases, supported by proof-of-concept data and regulatory encouragement for rare disease drug development[1][3].
Jaguar Health also formed family companies such as Napo Therapeutics (established in Milan in 2021) to expand crofelemer’s reach into European markets and rare disease indications, reflecting an evolving global strategy and focus on high-value niche markets[3].
---
---
Jaguar Health rides the trend of botanical and sustainable pharmaceutical innovation, combining natural product sourcing with modern drug development. The timing is favorable due to increasing regulatory openness to novel mechanisms for rare diseases and growing demand for non-opioid GI therapies. Market forces such as rising prevalence of chronic GI conditions, orphan drug incentives, and global interest in plant-based medicines work in Jaguar’s favor. By pioneering botanical prescription drugs, Jaguar influences the pharmaceutical ecosystem toward more sustainable, nature-derived therapeutics and expands treatment options for underserved patient populations[1][2][3].
---
Jaguar Health is poised for growth through clinical trial readouts, label expansions, and early access programs in rare GI diseases, which could significantly broaden crofelemer’s market. Trends shaping its journey include increasing regulatory support for orphan drugs, rising global demand for botanical medicines, and advances in GI disorder management. The company’s influence may evolve as a leader in botanical pharmaceuticals, potentially expanding into other therapeutic areas through joint ventures like Magdalena Biosciences for mental health indications. Continued innovation and geographic expansion will be critical to sustaining momentum and maximizing impact in the pharmaceutical landscape[1][3].
Jaguar Health has raised $7.0M in total across 1 funding round.
Jaguar Health's investors include BVCF (Bioveda China Fund).
Jaguar Health has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Series A in February 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2014 | $7.0M Series A | BVCF (Bioveda China Fund) |